Alflutop solution for injection, 1 mL, No. 10, in ampoules
excipients: phenol, water for injection.
Dosage Form
Solution for injection.
Main physicochemical properties: a clear solution free of suspended particles.
Pharmacotherapeutic group
Drugs used in disorders of the musculoskeletal system. ATX code M09A X.
Pharmacological properties
Pharmacodynamics.
The drug regulates metabolism in cartilage tissue.
It exerts a chondroprotective effect by normalizing the biosynthesis of hyaluronic acid and type II collagen and by inhibiting the activity of hyaluronidase and other enzymes involved in the degradation of the extracellular matrix. These effects stimulate the processes of cartilage structure repair and prevent the destruction of macromolecular structures in normal cartilage tissue.
By restoring homeostasis in the joint, the drug inhibits the biosynthesis of inflammatory mediators, including pro-inflammatory cytokines. As a result, the drug exerts a pronounced anti-inflammatory and analgesic effect, which becomes apparent on the 8th–10th day of treatment.
The proteoglycans in the drug exert trophic and reparative effects, significantly improving MRI parameters of hydrophilicity, cartilage height, and bone tissue homogeneity.
Pharmacokinetics.
The action of the marine organism extract is based on the cumulative effect of its active components; therefore, it is not possible to study its pharmacokinetic characteristics.
Indications
Degenerative-rheumatic joint diseases:
- osteoarthritis of various locations (coxarthrosis, gonarthrosis, osteoarthritis of small joints);
- spondylosis.
Recovery period following joint injuries and surgical procedures.
Contraindications
Contraindicated in cases of hypersensitivity to any component of the drug.
Interactions with Other Medications and Other Forms of Interaction
When Alflutop is used concomitantly with local anesthetics, particularly para-aminobenzoic acid derivatives (novocaine), the side effects of the latter should be taken into account.
Special Considerations
The drug should be used with caution under strict medical supervision, especially in cases of autoimmune diseases (rheumatoid polyarthritis, ankylosing spondylitis, systemic lupus erythematosus, scleroderma). The drug may cause anaphylactic reactions. It should be prescribed with caution to individuals with a history of allergies.
Pregnancy and Lactation
Do not use in pregnant or breastfeeding women.
Effects on the Ability to Drive and Operate Machinery
This medication does not affect the ability to drive or operate complex machinery.
Dosage and Administration
This medication is intended for adults.
Alflutop should be administered by deep intramuscular injection. The usual dose is 1 mL once daily; the course of treatment is 20 days.
In cases of large joint involvement, the drug should be administered intra-articularly at a dose of 1–2 mL, with a 3-day interval between injections. The course of treatment consists of 5 injections into each joint.
If medically indicated, the course of treatment should be repeated after 3–6 months.
Children
This medication should not be prescribed to children due to a lack of clinical data confirming its safety and efficacy in this age group.
Overdose
Some patients may experience allergic reactions.
Side Effects
Rare: changes at the injection site, including a burning sensation at the injection site and skin redness.
In rare cases: transient worsening of pain (following intra-articular administration due to increased metabolic activity and enhanced blood flow), transient myalgia. Cases of hypersensitivity reactions have also been reported, including rash, dermatitis, hives, itching, angioedema, and anaphylactic shock.
Shelf life
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C in the original packaging to protect from light.
Incompatibility
There are no data on incompatibility of Alflutop with other medications; therefore, Alflutop should not be mixed with any solutions in the same syringe.
Packaging
1 mL of solution in glass ampoules; 5 ampoules per blister pack; 2 blister packs together with the package insert in a cardboard box.
1 mL of solution in glass ampoules; 5 ampoules per blister pack with foil; 2 blister packs together with the package insert in a cardboard box.
Manufacturer
“Biotechnos” JSC.
Address
3–5 Gorunului St., Otopeni-Ilfov, ZIP code 075100, Romania / Gorunului St. No. 3-5, Otopeni, Ilfov County, ZIP Code 075100, Romania.
Similar products
Products from the same category












